Biotron Ltd (ASX: BIT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Biotron Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.34 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
902.38 million
Earnings per share
-0.004
Dividend per share
N/A
Year To Date Return
-82.47%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Biotron Ltd (ASX: BIT)
Latest News
Healthcare Shares
Guess which ASX healthcare stock is rocketing almost 50% on Friday
Share Gainers
Biotron share price rockets 38% on COVID trial results
Healthcare Shares
The Biotron (ASX:BIT) share price just exploded 86% on COVID drug update
Share Gainers
Why Biotron, Fortescue, Ramelius, & Temple & Webster are storming higher
Share Market News
Biotron share price rockets 47% higher on COVID-19 compound testing update
Share Market News
Biotron share price rockets 30% on latest antiviral drug data
Share Market News
Why the Biotron share price has soared 22% higher today
Share Gainers
Why Biotron, Karoon Energy, Pro Medicus, & WiseTech Global are pushing higher
Share Gainers
These ASX shares are fighting the spread of coronavirus
52-Week Highs
Why CSL and these ASX shares just hit 52-week highs
Share Gainers
Biotron share price jumps 70% in two days on coronavirus hopes
Share Gainers
Why Biotron, De Grey Mining, Kathmandu, & Nick Scali are storming higher
BIT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Biotron Ltd
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
BIT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Dec 2024 | $0.02 | $0.00 | 0.00% | 206,082 | $0.02 | $0.02 | $0.02 |
| 20 Dec 2024 | $0.02 | $0.00 | 0.00% | 249,482 | $0.02 | $0.02 | $0.02 |
| 19 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,986,476 | $0.02 | $0.02 | $0.02 |
| 18 Dec 2024 | $0.02 | $0.00 | 0.00% | 340,300 | $0.02 | $0.02 | $0.02 |
| 17 Dec 2024 | $0.02 | $0.00 | 0.00% | 59,235 | $0.02 | $0.02 | $0.02 |
| 16 Dec 2024 | $0.02 | $0.00 | 0.00% | 395,486 | $0.02 | $0.02 | $0.02 |
| 13 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,249,754 | $0.02 | $0.02 | $0.02 |
| 12 Dec 2024 | $0.02 | $0.00 | 0.00% | 414,359 | $0.02 | $0.02 | $0.02 |
| 11 Dec 2024 | $0.02 | $0.00 | 0.00% | 52,484 | $0.02 | $0.02 | $0.02 |
| 10 Dec 2024 | $0.02 | $0.00 | 0.00% | 76,882 | $0.02 | $0.02 | $0.02 |
| 09 Dec 2024 | $0.02 | $0.00 | 0.00% | 40,978 | $0.02 | $0.02 | $0.02 |
| 06 Dec 2024 | $0.02 | $0.00 | 0.00% | 505,067 | $0.02 | $0.02 | $0.02 |
| 05 Dec 2024 | $0.02 | $0.00 | 0.00% | 206,637 | $0.02 | $0.02 | $0.02 |
| 04 Dec 2024 | $0.02 | $0.00 | 0.00% | 283,570 | $0.02 | $0.02 | $0.02 |
| 03 Dec 2024 | $0.02 | $0.00 | 0.00% | 342,619 | $0.02 | $0.02 | $0.02 |
| 02 Dec 2024 | $0.02 | $0.00 | 0.00% | 357,092 | $0.02 | $0.02 | $0.02 |
| 29 Nov 2024 | $0.02 | $0.00 | 0.00% | 2,872,644 | $0.02 | $0.02 | $0.02 |
| 28 Nov 2024 | $0.02 | $0.00 | 0.00% | 2,054,298 | $0.02 | $0.02 | $0.02 |
| 27 Nov 2024 | $0.02 | $0.00 | 0.00% | 3,342,293 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 25 Nov 2024 | Michael Hoy | Expiry | 934,780 | $17,760 |
Options expired.
|
| 25 Nov 2024 | Robert Thomas | Expiry | 268,403 | $5,099 |
Options expired.
|
| 25 Nov 2024 | Michelle Miller | Expiry | 315,000 | $5,985 |
Options expired. As per announcement on 28-11-2024
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael J Hoy | Non-Executive DirectorNon-Executive Chairman | Feb 2000 |
Mr Hoy has more than 30 years of corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
|
| Mr Robert Bain Thomas | Non-Executive Director | Mar 2012 |
Mr Thomas has over 35 years of experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.
|
| Dr Michelle Miller | Managing Director | Jun 2002 |
Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson & Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
|
| Mr Peter James Nightingale | Company Secretary | Feb 1999 |
-
|
| Peter James Nightingale | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Rookharp Capital Pty Limited | 26,920,201 | 2.98% |
| Jey Investment Pty Ltd | 24,240,000 | 2.69% |
| Umbiram Pty Ltd <Michael Hoy Superfund A/C> | 11,217,352 | 1.24% |
| Fordholm Investments Pty Ltd <Fordholm Super Fund A/C> | 10,300,000 | 1.14% |
| Citicorp Nominees Pty Limited | 10,201,698 | 1.13% |
| Dr Angela Fay Dulhunty | 10,000,000 | 1.11% |
| Dr Huy Tran | 9,699,357 | 1.07% |
| Dns Accounting And Law Consultancy Pty Ltd | 8,359,582 | 0.93% |
| Attollo Copia Pty Ltd <F A Pires Super Fund A/C> | 7,620,678 | 0.84% |
| Pathold No 222 Pty Ltd | 7,600,000 | 0.84% |
| Armco Barriers Pty Ltd | 7,550,000 | 0.84% |
| Mr William John Dunn | 7,300,000 | 0.81% |
| Edstop Pty Limited <Superannuation Fund A/C> | 6,045,906 | 0.67% |
| Standby Forty Six Pty Limited | 5,600,000 | 0.62% |
| Vicex Holdings Proprietary Limited <Vicex Super A/C> | 5,600,000 | 0.62% |
| Scotts A V Pty Ltd <Scotts Acorn Emp S/F A/C> | 4,918,000 | 0.55% |
| Mr Travis Paul Gloury | 4,819,355 | 0.53% |
| Mr Charles Tollios Panos | 4,338,928 | 0.48% |
| Mr Peter James Nightingale | 4,313,884 | 0.48% |
| Mr Mark Andrew Peterson | 4,263,157 | 0.48% |
